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Technology transfer and local production can be an effective and sustainable strategy to access newer vaccines 
in developing countries.  The influenza pandemic in 2009 highlighted the importance of having a steady supply 
of vaccines to assure a controlled public-health strategy. To address these issues, Sinergium Biotech S.A. 
developed an innovative public-private partnership to transfer technology from multinational companies for local 
vaccine manufacturing. In doing so, it aimed to introduce long-lasting technology in Argentina, to support the 
steady supply of critical vaccines, and to generate regional exporting capacity. To date, the company has built a 
green field facility and has successfully completed three technology transfers from worldwide recognized 
technology providers, establishing state-of-the-art formulation and fill-finish capacity.  Sinergium Biotech 
currently supplies Influenza, Pneumococcal and HPV vaccines (approximately 18 million doses per year) from 
its current facility in the Buenos Aires suburbs to the Argentinian Ministry of Health.  In 2016, the company 
started a technology transfer to produce the FDA approved recombinant Influenza Vaccine Flublok® locally, 
including the production of the monovalent antigens.  To that end, Sinergium recently started the construction of 
a new facility that will produce recombinant antigens using the baculovirus expression system (BEVS).  The 
Sinergium Biotech development laboratory is currently working on a downscale process manufacturing model 
and analytical methods which are critical to support the future manufacturing activities. 
 
